Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127 USD | -0.85% | -1.03% | +2.39% |
Apr. 30 | Glutality Powered by StrideMD Announces Integration with Dexcom to Enhance Remote Diabetes Care with CGM Technology | CI |
Apr. 26 | Wall Street: the worst week of 2024 is followed by the best | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 67% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 72.39 and 58.86 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.39% | 50.53B | B- | ||
-4.84% | 182B | C+ | ||
+0.56% | 110B | C | ||
-3.35% | 68.11B | A | ||
+9.36% | 44.8B | B- | ||
+2.70% | 40.7B | B+ | ||
+3.43% | 26.53B | A- | ||
+13.67% | 25.02B | A- | ||
-0.32% | 24.96B | B | ||
+5.22% | 22.86B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DXCM Stock
- Ratings DexCom, Inc.